Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024 Apr 18; 143(16):1616-1627.